RDY
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Dr. Reddy's Laboratories Ltd is an integrated global pharmaceutical company established in 1984. The company operates through three reportable segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products, including small- and large-molecule generics, biosimilars, and consumer healthcare brands such as Nicotinell and Nicabate. The PSAI segment provides active pharmaceutical ingredients, intermediates, and contract research and manufacturing services to pharmaceutical partners. The Others segment includes Aurigene Oncology Limited, a discovery-stage biotechnology company focused on oncology and inflammation, and a proprietary products business developing differentiated formulations. Key markets include the United States, India, Russia, other former Soviet Union countries, and Europe. The company maintains partnerships with Alvotech, Shanghai Henlius Biotech, Nestlé Health Science India, Takeda, and Gilead Sciences for the commercialization of biosimilars, nutritional products, and HIV prevention therapies.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Drug Manufacturers - General Homepage drreddys.com
Sector Healthcare IR page drreddys.com/investor
Tags
generics, biosimilars, active pharmaceutical ingredients, contract research, consumer healthcare, nicotine replacement therapy, oncology, inflammation, small molecules, large molecules, Nicotinell, Nicabate, Aurigene Oncology Limited, Aurigene Discovery Technologies Limited, NIVORZ, QDENGA, lenacapavir, daratumumab biosimilar HLX15, Prolia, Xgeva, denosumab, Northstar Switzerland SARL, Haleon UK Enterprises Limited, Nestlé Health Science India, Alvotech, Shanghai Henlius Biotech Inc., Takeda, Gilead Sciences, MedEngage, DocVidya, Medepro, Medenrich, Medznat, Info-Jini
Press page —

Metrics

Valuation  
Market cap INR 10.5B
Market cap (USD) $ 112.364M
P/E 23.52
PEG —
P/BV 2.64
P/S 3.00
P/OCF 17.73
P/FCF 30.10
Dividend yield 0.66%
Turnover / mcap —
Returns  
ROE 11.8%
ROI 10.7%
ROIC 9.8%
Profit margin 12.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -1.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 4.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score 21.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 335.933B 325.535B 279.164B 245.879B 214.391B 189.722B 174.6B 153.851B 2.176B 140.809B 154.708B 148.189B 132.17B 116.266B
Net profit 42.466B 57.245B 55.684B 45.067B 23.568B 17.238B 19.498B 18.795B 152.234M 12.039B 20.013B 22.179B 21.515B 16.777B
Free cash flow 33.429B 18.924B 29.03B 47.552B 13.448B 25.962B 24.995B 21.749B — 9.235B 29.23B 15.694B 9.382B 6.647B

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.299K 1.114K 6.107K 4.678K 4.176K 4.53K 2.873K 2.922K 34.01 2.706K 2.979K 3.536K 2.723K 1.751K
Price performance 12m 0.05 -0.82 0.29 0.02 -0.09 0.52 -0 0.24 — -0.11 -0.21 0.3 0.36 -0.06

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Borrowings, current (INR) 43.6B — — — — — — — — —
Cash and deposits (INR) 3.87B — — — — — — — — —
Intangible assets (INR) 44.9B — — — — — — — — —
Net debt (borrowings + leases - cash) (INR) 39.8B — — — — — — — — —
Cash flow detail
Operating cash flow (INR) 21.5B — — — — — — — — —
Change in inventories (cash effect) (INR) 6.33B — — — — — — — — —
Interest paid (cash effect) (INR) -925M — — — — — — — — —
Income taxes paid (cash effect) (INR) -5.77B — — — — — — — — —
Share-based compensation (INR) 398M — — — — — — — — —
Income detail
Research and development expense (INR) 19.6B 18.3B 226M 204M 226M 230M 236M 274M 320M 256M
↳ 5y CAGR +27.0% +18.9% +3.9% +9.4% +2.5%
Reported Jun 19, 2017 Jun 3, 2019 Jun 3, 2019 Jun 15, 2020 Jun 30, 2021 Jun 27, 2022 Jun 13, 2023 Jun 12, 2024 Jun 6, 2025 May 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

NSE IFSC Ltd. (Stock Code: DRREDDY) Bull 0 Bear 0 Routine

Dear Sir/Madam,

Ref:

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is in reference to our intimation dated August 14, 2026, wherein we had informed regarding the Good Manufacturing Practices (GMP) inspection conducted by the United States Food & Drug Administration (USFDA) at our formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad. We wish to inform you that the USFDA has classified the inspection outcome as ‘Voluntary Action Indicated (VAI)’ and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3).

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Fax: + 91 40 4900 2999 Email: [email protected]

November 10, 2026

NSE IFSC Ltd. (Stock Code: DRREDDY)

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings

This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups:

Date Organized by Location Meeting mode Nature of meet Timing

16.11.2026 JM Financial Mumbai In-Person Group Meet 10:00 - 17:00 IST

17.11.2026 – 18.11.2026 Investec London In-Person Group Meet 09:00 - 17:00 GMT

Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.

This is for your information.

Thanking you.

Yours faithfully, For Dr. Reddy’s Laboratories Limited

K Randhir Singh Company Secretary, Compliance Officer & Head-CSR

NSE IFSC Ltd. (Stock Code: DRREDDY) Bull 3 Bear 0 Clinical/regulatory

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find enclosed a Press Release viz. “Dr. Reddy’s receives marketing authorization for generic semaglutide injection in Brazil.”

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500034. Telangana, India.

CONTACT

CIN: L85195TG1984PLC004507

INVESTOR RELATIONS

MEDIA RELATIONS

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

AISHWARYA SITHARAM

SANTOSH VYAS

Email: [email protected]

[email protected]

[email protected]

Web: www.drreddys.com

Dr. Reddy’s receives marketing authorization for generic semaglutide injection in Brazil

• ANVISA grants marketing authorization for generic semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise

• The approval expands Dr.

Prompts

Dr. Reddy's Laboratories Ltd (ticker RDY), listed in United States.

ETFs Holding Dr. Reddy's Laboratories Ltd

ETF Weight in ETF Shares Market value As of
EMOP 2.54% 3,717,214 $ 53.862M Jun 30, 2026
EMEQ 0.29% 136,250 $ 1.974M Jun 30, 2026
JEMA 0.12% 130,354 $ 1.928M Nov 17, 2026
DFEV 0.11% 158,614 $ 2.336M Nov 12, 2026
AVXC 0.10% 28,170 $ 414.099K Nov 16, 2026
AVEM 0.09% 1,586,071 $ 23.315M Nov 16, 2026
DFSE 0.09% 34,164 $ 503.236K Nov 12, 2026
DEXC 0.09% 15,347 $ 226.061K Nov 12, 2026
APIE 0.08% 75,648 $ 917.61K Aug 31, 2026
DFEM 0.06% 382,908 $ 5.64M Nov 12, 2026
DFAE 0.06% 362,865 $ 5.345M Nov 12, 2026
AVSE 0.05% 7,213 $ 106.031K Nov 16, 2026
DFAX 0.04% 331,226 $ 4.879M Nov 12, 2026